Oleanane derivatives for pharmaceutical use: a patent review (2000-2016)

References

• Kumari S, Priya P, Misra G, et al. Structural and biochemical perspectives in plant isoprenoid biosynthesis. Phytochem Rev. 2013;12:255–291.
   Web of Science ®Google Scholar
• Ruzicka L. Isoprene rule and the biogenesis of terpenic compounds. Experientia. 1953;9:357–367.
   PubMedGoogle Scholar
• Parikh NR, Mandal A, Bhatia D, et al. Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives. Phytochem Rev. 2014;13:793–810.
   PubMed Web of Science ®Google Scholar
• Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer. 2007;7:357–369.
   PubMed Web of Science ®Google Scholar
• Pollier J, Goossens A. Oleanolic acid. Phytochemistry (Elsevier). 2012;77:10–15.
   PubMed Web of Science ®Google Scholar
• Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012;64:972–1003.
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT, Yore MM, et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod. 2011;74:537–545.
   PubMed Web of Science ®Google Scholar
• Wang X, Ye XL, Liu R, et al. Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases. Chem-Biol Interact. 2010;184:328–337.
   PubMed Web of Science ®Google Scholar
• Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 2009;75:1549–1560.
   PubMed Web of Science ®Google Scholar
• Yin M-C, Lin M-C, Mong M-C, et al. Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice. J Agric Food Chem. 2012;60:7697–7701.
   PubMed Web of Science ®Google Scholar
• Honda T, Rounds BV, Bore L, et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem. 2000;43:4233–4246.
   PubMed Web of Science ®Google Scholar
• Honda T, Rounds BV, Bore L, et al. Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett. 1999;9:3429–3434.
   PubMed Web of Science ®Google Scholar
• Honda T, Rounds BV, Gribble GW, et al. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett. 1998;8:2711–2714.
   PubMed Web of Science ®Google Scholar
• Honda T, Gribble GW, Suh N, et al. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J Med Chem. 2000;43:1866–1877.
   PubMed Web of Science ®Google Scholar
• Suh N, Honda T, Finlay HJ, et al. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 1998;58:717–723.
   PubMed Web of Science ®Google Scholar
• Suh N, Wang Y, Honda T, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999;59:336–341.
   PubMed Web of Science ®Google Scholar
• Honda T, Honda Y, Favaloro FG, et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett. 2002;12:1027–1030.
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby K, Yore MM, et al. Platforms and networks in triterpenoid pharmacology. Drug Dev Res. 2007;68:174–182.
   Web of Science ®Google Scholar
• Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A. 2005;102:4584–4589.
   PubMed Web of Science ®Google Scholar
• Honda T, Honda Y, Gribble GW, et al. Preparation of triterpenoid derivatives as inhibitors of nitric oxide production. US20040002463A1. 2004.
   Google Scholar
• Liby K, Royce DB, Williams CR, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007;67:2414–2419.
   PubMed Web of Science ®Google Scholar
• Onyango EO, Fu LF, Cao M, et al. Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO). Bioorg Med Chem Lett. 2014;24:532–534.
   PubMed Web of Science ®Google Scholar
• Sheng H, Sun H. Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases. Nat Prod Rep. 2011;28:543–593.
   PubMed Web of Science ®Google Scholar
• Sporn M, Liby K, Gribble G, et al. Novel amide derivatives of CDDO and methods of use thereof. WO2008136838A1. 2008.
   Google Scholar
• Patel S, Masonson H. Methods for treating or preventing ophthalmological diseases using a PDGF antagonist and a VEGF antagonist. WO2010127029A1. 2010.
   Google Scholar
• Chin MP-H, Meyer CJ. Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof. WO2015027206A1. 2015.
   Google Scholar
• Sporn MB, Lyby KT, Gribble GW, et al. Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions by inducing gene expression and differentiation of stem or progenitor cells. US20130089526A1. 2013.
   Google Scholar
• Sporn MB, Liby KT, Honda T, et al. Synthesis of triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth. WO2008064132A2. 2008.
   Google Scholar
• Wahl SM, Vazquez-Maldonado N, Greenwell-Wild T. Methods and compositions for the inhibition of HIV-1 replication in hum an cells using inhibitors of p21/CDKN1A activity or gene expression, and anti-AIDS uses. WO2005046732A2. 2005.
   Google Scholar
• Konopleva M, Andreef M, Sporn M. CDDO (2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid) compounds and combinations with other chemotherapeutics for the treatment of cancer and graft vs. host disease. WO2002047611A2. 2002.
   Google Scholar
• Sporn M, Liby K, Gribble GW, et al. Synthetic triterpenoids and methods of use in the treatment of disease. WO2009089545A1. 2009.
   Google Scholar
• Jiang X, Greiner J, Maravetz LL, et al. Antioxidant inflammation modulators: novel oleanolic acid derivatives. WO2009146216A2. 2009.
   Google Scholar
• Anderson E, Jiang X, Visnick M. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives. WO2009129546A1. 2009.
   Google Scholar
• Jiang X, Bender CF, Visnick M. Preparation of C17-heteroaryl derivatives of oleanolic acid as anti-inflammatory agents. WO2014040056A1. 2014.
   Google Scholar
• Bender CF, Jiang X, Anderson E, et al. Preparation of C17-alkanediyl and alkanediyl derivatives of oleanolic acid as anti-inflammatory agents and antioxidants. WO2014040060A1. 2014.
   Google Scholar
• Sporn MB, Liby KT, Cao M, et al. CDDO-Me amino acid conjugates and methods of use. US20150225352A1. 2015.
   Google Scholar
• Anderson E, Decker A, Liu X. Synthesis, pharmaceutical use, and characterization of crystalline forms of 2,2-difluoropropionamide derivatives of bardoxolone methyl. WO2013163344A1. 2013.
   Google Scholar
• Anderson E, Bender CF, Jiang X, et al. Methods of preparation and use of A-ring epoxidized triterpenoid-based anti-inflammation modulators. WO2013188818A1. 2013.
   Google Scholar
• Liby K, Hock T, Yore MM, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005;65:4789–4798.
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhe H, Zhao R. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol Cancer. 2014;13:30.
   Web of Science ®Google Scholar
• Qin D-J, Tang C-X, Yang L, et al. Hsp90 is a novel target molecule of CDDOMe in inhibiting proliferation of ovarian cancer cells. PLoS One. 2015;10:1–10.
   Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Supko JG, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012;18:3396–3406.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365:327–336.
   PubMed Web of Science ®Google Scholar
• Chin MP, Reisman SA, Bakris GL, et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014;39:499–508.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492–2503.
   PubMed Web of Science ®Google Scholar
• Wong MHL, Bryan HK, Copple IM, et al. Design and synthesis of irreversible analogues of bardoxolone methyl for the identification of pharmacologically relevant targets and interaction sites. J Med Chem. 2016;59:2396–2409.
   PubMed Web of Science ®Google Scholar
• Future development direction for bardoxolone methyl (RTA 402). Kyowa Kirin, Kyowa Hakko Kirin Co., Ltd.; 2014 Jul 2. Available from: http://www.kyowa-kirin.com/news_releases/2014/e20140702_01.html
   Google Scholar
• Reata Pharmaceuticals, Inc. Announces interim data from extension phase 2 LARIAT study in pulmonary arterial hypertension. Reata Pharmaceuticals, Inc.; 2016 Jun 23. Available from: http://investors.reatapharma.com/phoenix.zhtml?c=254306&p=irol-newsArticle&ID=2179606
   Google Scholar
• Rong F, Xu R, Xie F, et al. Oleanolic acid amidate derivatives useful in treatment of cancer and their preparation. WO2013079024A1. 2013.
   Google Scholar
• Xu R, Rong F, Lai H, et al. 2-Substituted oleanolic acid deriv. useful in treatment of cancer and its preparation. WO2013079018A1. 2013.
   Google Scholar
• Rabi T, Huwiler A, Zangemeister-Wittke U. AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells. Mol Carcinog. 2014;53:578–588.
   PubMed Web of Science ®Google Scholar
• Rabi T, Wang L, Banerjee S. Novel triterpenoid 25-hydroxy-3-oxoolean-12-en-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Breast Cancer Res Treat. 2007;101:27–36.
   PubMed Web of Science ®Google Scholar
• Bishayee A, Martirosian A, Yeranosyan A. Preparation of amooranin compounds and analogs thereof and related therapeutic uses. WO2013101719A2. 2013.
   Google Scholar
• Eldridge GR, Buckle RN, Ellis M, et al. Preparation of heterocyclic-fused triterpenes as inhibitors of bacterial biofilms and related methods. US8324264B1. 2012.
   Google Scholar
• Bradbury BJ, Soper SJ, Kaczvinsky JR Jr., et al. Compositions which contain triterpenes for regulating hair growth. US6482857B1. 2002.
   Google Scholar
• Bradbury JB, Schafer SJ, Kaczvinsky JR Jr., et al. Method for regulating hair growth. WO2000003749A2. 2000.
   Google Scholar
• Bradbury JB, Schafer SJ, Kaczvinsky JR Jr., et al. Compositions which contain triterpenes for regulating hair growth. WO2000003748A2. 2000.
   Google Scholar
• Vincken J-P, Heng L, De Groot A, et al. Saponins, classification and occurrence in the plant kingdom. Phytochemistry (Elsevier). 2007;68:275–297.
   PubMed Web of Science ®Google Scholar
• Augustin JM, Kuzina V, Andersen SB, et al. Molecular activities, biosynthesis and evolution of triterpenoid saponins. Phytochemistry (Elsevier). 2011;72:435–457.
   PubMed Web of Science ®Google Scholar
• Sjolander A, Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Delivery Rev. 1998;34:321–338.
   PubMed Web of Science ®Google Scholar
• Wang P. Natural saponin-based synthetic oligosaccharide uronates as immunoadjuvants. WO2013142142A1. 2013.
   Google Scholar
• Gin DY, Chea EK, Fernandez-Tejada A, et al. Preparation of oligosaccharide triterpene saponin analogs and may be used as immunostimulants and adjuvants in cancer vaccines. WO2015184451A1; 2015.
   Google Scholar
• Garçon N, Leroux-Roels G, Cheng W-F. Vaccine adjuvants. Perspect Vaccinology. 2011;1:89–113.
   Google Scholar
• Jacobsen NE, Fairbrother WJ, Kensil CR, et al. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydr Res. 1996;280:1–14.
   PubMed Web of Science ®Google Scholar
• Bourguignon PB, Koutsoukos MC, Lorin CM-M. Glycoprotein gp120env-based vaccines for prophylaxis of AIDS. WO2015036061A1. 2015.
   Google Scholar
• Ballou WR Jr., Didierlaurent AM, Van der Most RG. Improved methods for malaria vaccination by at least two vaccine administrations, wherein a lower dose is given in the second administration. WO2015150568A1. 2015.
   Google Scholar
• Angov E, Bergmann-Leitner E, Ockenhouse CF, et al. Novel malaria vaccines. WO2015091734A1. 2015.
   Google Scholar
• Dominowski PJ, Rai SK, Sly LM, et al. Novel vaccine compositions comprising immunostimulatory oligonucleotides. WO2014186291A1. 2014.
   Google Scholar
• Quinnan GV, Broder CC, Voss GH, et al. Human immunodeficiency virus-1 immunogens. WO2007133573A1. 2007.
   Google Scholar
• De Cassan S, Douglas A, Draper S, et al. Adjuvanted viral vector vaccines. WO2012042279A2. 2012.
   Google Scholar
• Tony Yu CD, Lee WH, Wang N-H, et al. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant. WO2014107652A2. 2014.
   Google Scholar
• Bazmorelli A, Maraskovsky E. Anti-tumor vaccine. US20150037374A1. 2015.
   Google Scholar
• Bruck CEM, Brichard V, Palmantier RM, et al. Vaccines comprising MAGE-3/NY-ESO-1 antigen and immune adjuvant for treating cancer. WO2005105139A2. 2005.
   Google Scholar
• Marciani DJ. Vaccine formulations that induce a Th2 immune response. WO2015017280A1. 2015.
   Google Scholar
• Vandepapeliere P. Novel vaccine compositions that induce immune response. WO2007068907A2. 2007.
   Google Scholar
• Mossman S, Evans L. Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21. US20030147920A1. 2003.
   Google Scholar
• Srivastava PK. Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease. WO2005120558A2. 2005.
   Google Scholar
• Gin D, Adams M, Deng K, et al. Preparation of triterpene saponin-containing oligosaccharide uronates and their use as antitumor agents and antiviral vaccines. WO2009126737A2. 2009.
   Google Scholar
• Man S-L, Gao W-Y, Zhang Y-J, et al. Chemical study and medical application of saponins as anti-cancer agents. Fitoterapia. 2010;81:703–714.
   PubMed Web of Science ®Google Scholar
• Wang Z-P. Saponins as anticancer agents. US20050175623A1. 2005.
   Google Scholar
• Arntzen CJ, Tracey MB, Gutterman JU, et al. Triterpene glycosides of Acacia victoriae as antitumor agents. WO9959578A1. 1999.
   Google Scholar
• Jayatilake GS, Freeberg DR, Liu Z, et al. Isolation and structures of avicins d and g: in vitro tumor-inhibitory saponins derived from acacia victoriae. J Nat Prod. 2003;66:779–783.
   PubMed Web of Science ®Google Scholar
• Gutterman J, Haridas V, Michels PC, et al. Cytoprotective derivatives of avicin D and methods of preparation and use. WO2014100700A1. 2014.
   Google Scholar
• Michels PC, Khmelnitsky YL, Gutterman J, et al. Preparation of avicin D derivatives as antitumor agents. WO2013126730A1. 2013.
   Google Scholar
• Stamler JS, Gutterman J. Compositions for the reversible thioesterification of signaling proteins and methods of using same. WO2007011985A1. 2007.
   Google Scholar
• Gutterman JU. Stents coated with avicins. WO2006034345A2. 2006.
   Google Scholar
• Hickie R, Balsevich J, Ramirez-Erosa I, et al. Saponin extract from Saponaria spp. for treating cancer. WO2009117828A1. 2009.
   Google Scholar
• Zee OP, Kang SC, Kwak JH, et al. Anticancer activity of Androsace umbellata Merr. extract and contained triterpene saponin. WO2007037598A1. 2007.
   Google Scholar
• Meesapyodsuk D, Balsevich J, Reed DW, et al. Saponin biosynthesis in Saponaria vaccaria. cDNAs encoding β-amyrin synthase and a triterpene carboxylic acid glucosyltransferase. Plant Physiol. 2007;143:959–969.
   PubMed Web of Science ®Google Scholar
• Gruza MM, Jatczak K, Zagrodzki B, et al. Preparation, purification and regioselective functionalization of protoescigenin - the main aglycone of escin complex. Molecules. 2013;18:4389–4402.
   PubMed Web of Science ®Google Scholar
• Chan P-K, Mak MS. New natural and synthetic compounds for treating cancer and other diseases. US20140199378A1. 2014.
   Google Scholar
• Chan P-K, Mak MS. Method of synthesizing new active compounds for pharmaceutical uses including cancer. US20120277308A1. 2012.
   Google Scholar
• Chan P-K, Mak MS. Inhibition of metastatic invasion of cancer cells. WO2011009032A1. 2011.
   Google Scholar
• Chan P-K, Mak MS, Wang Y. Anti-tumor compounds with angeloyl groups. US20070161580A1. 2007.
   Google Scholar
• Chan P-K, Mak MS. Xanifolia triterpenoid saponin compounds for blocking the migration or metastasis of cancer cells by affecting adhesion proteins. WO2008133766A1. 2008.
   Google Scholar
• Chan P-K, Mak MS, Wang Y. Antitumor compounds with angeloyl groups. WO2006029221A2. 2006.
   Google Scholar
• Chan P-K, Mak MS, Wang Y. Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same, and uses thereof. US20050276872A1. 2005.
   Google Scholar
• Guang C, Chen J, Sang S, et al. Biological functionality of soyasaponins and soyasapogenols. J Agric Food Chem. 2014;62:8247–8255.
   PubMed Web of Science ®Google Scholar
• Rosazza JPN, Hosny M. Isoflavone and triterpene glycosides from soybeans. WO2003088907A2. 2003.
   Google Scholar
• Wu C-Y, Chen S-T, Tsai Y-C. Saponin derivatives useful for inhibiting sialyltransferase and biosynthesis of sialoglycoconjugate. US20020115623A1. 2002.
   Google Scholar
• Lowe JA. Synergistic molluscicidal saponin compositions. WO2000004781A1; 2000.
   Google Scholar
• Gan D, Florence T, Hines M, et al. Compositions containing plant extracts for the treatment of sensitive skin. WO2015077618A1. 2015.
   Google Scholar
• Prieschl-Grassauer E, Friedrich T. Use of escin for treatment of Type IV hypersensitivity reaction. WO2010057856A1. 2010.
   Google Scholar
• Di Pierro F. Topical formulations comprising capsaicin, boswellic acids, and escin for symptomatic treatment of musculoskeletal disorders. EP2149378A1. 2010.
   Google Scholar
• Grassauer A, Prieschl E. Use of escin the treatment of diseases mediated or caused by activated granulocytes. EP1884245A1. 2008.
   Google Scholar
• Florence T, Hines M, Gan D. Cosmetic compositions and uses thereof. US20140271508A1. 2014.
   Google Scholar
• Aleotti A. Cosmetic composition comprising aryldimethylpyrazolone designed to reduce unsightly cellulite. WO2008116602A1. 2008.
   Google Scholar
• Landini M, Giuliani S, Giolitti A. Pharmaceutical compositions containing phosphodiesterase-3 for the treatment of cellulite. WO2006063714A1. 2006.
   Google Scholar
• Di Pierro F. Pharmaceutical and/or cosmetic compositions for the treatment of localized adiposities and cellulite. WO2002098436A1. 2002.
   Google Scholar
• Chan P-K, Mak MS. Terpenoid saponin compounds for blocking the metastasis of cancer cells and as antiparasitic agents. WO2009117196A1. 2009.
   Google Scholar
• Calton GJ. Soyasaponin plus amino acids for treating kidney disease. US20070141121A1. 2007.
   Google Scholar
• Feng X, Ding L, Qiu F. Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid. Drug Metab Rev. 2015;47:229–238.
   PubMed Web of Science ®Google Scholar
• Gremillet C, Garcia R, Lemaire E. Formulations comprising S-adenosyl-methionine, quercetin and glycyrrhizin for liver health. WO2015071373A1. 2015.
   Google Scholar
• Zabrecky G. Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis. US20050123628A1. 2005.
   Google Scholar
• Utsunomiya K. Use of glycyrrhizin for the treatment of standard therapy-resistant hepatitis C patients. WO2004056374A1; 2004.
   Google Scholar
• Flore O. Composition for and method of treatment of Kaposi’s sarcoma and Kaposi’s sarcoma-assocd. herpesvirus infection using triterpenoids. US6323183B1. 2001.
   Google Scholar
• Mercuri L. Pharmaceutical composition based on glycyrrhizin and EG56 polymer for the preparation of anti-inflammatory products. WO2011111084A1. 2011.
   Google Scholar
• Mayne JR, Roh-Schmidt H. Topical anti-inflammatory compositions and methods of reducing inflammation. US20030143288A1. 2003.
   Google Scholar
• Kobayashi M, Matsumoto H, Suzuki F, et al. Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors. EP1419777A1. 2004.
   Google Scholar
• Cinatl J, Doerr HW, Hover G, et al. Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome. WO2004108122A1. 2004.
   Google Scholar
• Kobayashi M, Matsumoto H, Iwata S, et al. Use of glycyrrhizin and its derivatives as RANTES inducers. EP1421942A1. 2004.
   Google Scholar
• Khanuja SPS, Kumar S, Arya JS, et al. A composition comprising pharmaceutical/nutraceutical agent and a bioenhancer obtained from Glycyrrhiza glabra. WO2002017939A1. 2002.
   Google Scholar
• Ford SR. Camellia sinensis saponins as molluscicidal agents and uses thereof. WO2012150573A1. 2012.
   Google Scholar
• Silberstein T. Formulations comprising natural saponins with antimicrobial effects and uses thereof. WO2012077119A2. 2012.
   Google Scholar
• Bengtsson MV, Hockenhull JR, Elgaard T, et al. Natural fungicide and plant growth promoter. EP1867230A2. 2007.
   Google Scholar
• Van Dijck P, Tournu H, Luyten W, et al. Anti-fungal compositions comprising plant-derived saponins such as momordin Ic. WO2015032964A1. 2015.
   Google Scholar
• Maes LJRM, Germonprez NAG, Van Puyvelde LEM, et al. Isolation of triterpene saponins from Myrsinaceae for treating leishmaniases. WO2000038700A1. 2000.
   Google Scholar
• Lee E-B, Li DW. Composition containing an ethyl acetate-soluble extract from Kalopanax pictus Nakai and kalopanaxsaponin A derivatives isolated therein for protecting and treating inflammatory and rheumatic disease. WO2003099305A1. 2003.
   Google Scholar
• Wahidullah S, Bhosak SH, D’Souza MLD. A composition containing novel compound corniculatonin having antifungal properties and a process for preparing the same. WO2002077008A1. 2002.
   Google Scholar